Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer

Combined chemotherapy and radiofrequency electromagnetic field treatment for patients with liver dominant refractory metastatic colorectal cancer

Trial Details

NCT ID
NCT05991102
Phase
NA
Sponsor
Charite University, Berlin, Germany
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Radiofrequency electromagnetic field treatment
Locations (sample)
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Written informed consent prior to any study procedure
  • 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Histologically confirmed colorectal cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →